DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
Ce qui change
The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.
Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.
Pourquoi c’est important
Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.
À surveiller
Le signal utile n’est pas seulement le chiffre du titre, mais la capacité du produit, du contrat ou du virage de plateforme à se répéter sur les deux prochains trimestres.
Sources: CocoLoop